Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

J. Shapiro, J.J.B. van Lanschot, M.C.C.M. Hulshof, P. van Hagen, M.I.V. Henegouwen, B.P.L. Wijnhoven, H.W.M. van Laarhoven, G.A.P. Nieuwenhuijzen, G.A.P. Hospers, J.J. Bonenkamp, M.A. Cuesta, R.J.B. Blaisse, O.R.C. Busch, F.J.W. Ten Kate, G.J.M. Creemers, C.J.A. Punt, J.T.M. Plukker, H.M.W. Verheul, E.J.S. Bilgen, H. van DekkenM.J.C. van der Sangen, T. Rozema, K. Biermann, J.C. Beukema, A.H.M. Piet, C.M. van Rij, J.G. Reinders, H.W. Tilanus, E.W. Steyerberg, A. van der Gaast

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1090-1098
JournalLancet Oncology
Volume16
Issue number9
DOIs
Publication statusPublished - 2015

Cite this

Shapiro, J., van Lanschot, J. J. B., Hulshof, M. C. C. M., van Hagen, P., Henegouwen, M. I. V., Wijnhoven, B. P. L., ... van der Gaast, A. (2015). Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncology, 16(9), 1090-1098. https://doi.org/10.1016/S1470-2045(15)00040-6